Study of Rilvegostomig or Durvalumab plus chemo for biliary tract cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests two immunotherapy drugs (rilvegostomig or durvalumab) combined with standard chemotherapy for people with bile duct or gallbladder cancer that has spread or cannot be removed. It aims to see if these combinations work better than chemo alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have bile duct cancer (inside or outside the liver) or gallbladder cancer confirmed by a biopsy.
- Your cancer must be advanced (spread) or cannot be surgically removed, and you have not had any prior treatment for advanced disease.
- Your tumor must have measurable disease on a CT or MRI scan.
- You must be in good overall health (able to do daily activities without help) with blood counts and organ function within normal limits.
- You cannot have active autoimmune disease, lung inflammation (pneumonitis), or serious digestive issues requiring steroids or other immune-suppressing medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy, immunotherapy, and heat therapy (hyperthermia) with a special radiation technique for advanced bile duct or gallbladder cancer that hasn't been treated before. It aims to see if this combination can help shrink tumors and improve outcomes.
This trial tests a combination of chemotherapy drugs given directly into the liver, combined with two immunotherapy/targeted therapy drugs, for people with advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The goal is to shrink tumors and improve survival in patients who have not received prior chemotherapy.
This trial tests a combination of two drugs, pemigatinib and durvalumab, in people with a certain type of advanced bile duct cancer that has a specific genetic change (FGFR2 fusion or rearrangement). The goal is to see if this combination can help when standard treatments have stopped working.
This trial tests whether adding an immunotherapy drug (rilvegostomig) to standard chemotherapy before surgery can improve outcomes for patients with early-stage bile duct cancer that can be completely removed. The treatment aims to shrink the tumor and help prevent the cancer from coming back.
This study tests a new combination of two drugs (recaticimab and adebrelimab) with standard chemotherapy for people with bile duct or gallbladder cancer that cannot be removed by surgery. The goal is to see if this combination helps shrink tumors and slow the cancer's growth.
This trial is testing a new combination of treatments—a wearable device that sends electric fields to the tumor area (tumor-treating fields) plus immunotherapy (durvalumab) and chemotherapy (gemcitabine/cisplatin)—for people with advanced bile duct or gallbladder cancer. It may be an option if you haven't had chemotherapy for advanced disease before.
Hear when a new Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.